ANDREW YEE to Multiple Myeloma
This is a "connection" page, showing publications ANDREW YEE has written about Multiple Myeloma.
Connection Strength
2.175
-
Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma. Blood Adv. 2025 Mar 11; 9(5):1163-1170.
Score: 0.778
-
Prospective study of immunogenicity to SARS-CoV-2 booster vaccines in multiple myeloma and Waldenstr?m macroglobulinemia. Blood Adv. 2025 Sep 23; 9(18):4568-4579.
Score: 0.202
-
Psychosocial and NF-?B Activity Effects of the Stress Management and Resiliency Training: Relaxation Response Resiliency Program (SMART-3RP) on Patients With MGUS and Smoldering Multiple Myeloma: A Randomized Waitlist Control Trial. Psychooncology. 2025 Jul; 34(7):e70216.
Score: 0.199
-
Integration of clinical outcomes and molecular features in extramedullary disease in multiple myeloma. Blood Cancer J. 2024 12 23; 14(1):224.
Score: 0.192
-
Phase 1 first-in-human study of MEDI2228, a BCMA-targeted ADC, in patients with relapsed refractory multiple myeloma. Leuk Lymphoma. 2024 Dec; 65(12):1789-1800.
Score: 0.189
-
Targeting Ikaros and Aiolos: reviewing novel protein degraders for the treatment of multiple myeloma, with a focus on iberdomide and mezigdomide. Expert Rev Hematol. 2024 Aug; 17(8):445-465.
Score: 0.186
-
Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma. Cancer Cell. 2022 11 14; 40(11):1358-1373.e8.
Score: 0.166
-
Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee. Blood Cancer J. 2022 06 29; 12(6):98.
Score: 0.161
-
Cutaneous involvement in multiple myeloma: a multi-institutional retrospective study of 53 patients. Leuk Lymphoma. 2016 09; 57(9):2071-6.
Score: 0.103